Articles By Janet Pope, MD, MPH, FRCPC

question-mark-1872634_640.jpg

Combining a Tyk2 inhibitor with a JAKi in RA?

By Janet Pope, MD, MPH, FRCPC

At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.

Read Article
takayasu.jpg

New treatment for Takayasu’s arteritis?

By Janet Pope, MD, MPH, FRCPC

Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.

Read Article
lupus_0.jpg

The future of lupus treatment is oral therapies?

By Janet Pope, MD, MPH, FRCPC

There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies. But, what about the JAKis and Tyk2 oral drugs in SLE?

Read Article
signs treat

Why treatment of pre-RA isn't ready for prime time

By Janet Pope, MD, MPH, FRCPC

The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?

Read Article
pill pillbox adherence

Medication adherence is a problem

By Janet Pope, MD, MPH, FRCPC

Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects). This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.

Read Article
meeting education

Don’t be ‘ticked’: TYK2 is not a JAK!

By Janet Pope, MD, MPH, FRCPC

Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.

Read Article
heart.jpg (keep)

CV risk factors not equal when considering magnitude of risk

By Janet Pope, MD, MPH, FRCPC

What can we learn from Oral Surveillance? The Oral Surveillance trial has almost become a household word for rheumatologists.

Read Article
TYK2i

Are TYK2 inhibitors ‘ticked’ to be part of the JAK family?

By Janet Pope, MD, MPH, FRCPC

Are TYK2 inhibitors JAK inhibitors? Are they effective in PsA? Are they safer than JAKi? Read on to learn more.

Read Article
heart.jpg (keep)

Best of 2021: Perspectives on CV safety: JAKi (Tofacitinib) and TNF inhibitors

By Janet Pope, MD, MPH, FRCPC

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

By Janet Pope, MD, MPH, FRCPC

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
Profile picture for user Janet Pope, MD, MPH, FRCPC
  • Janet Pope, MD, MPH, FRCPC

  • Dr. Janet Pope is a Professor of Medicine in the Division of Rheumatology at the University of Western Ontario (UWO), Schulich School of Medicine, London, Ontario, Canada.  She is the Division Head in Rheumatology at St. Joseph's Health Centre, London. Her research includes studies in scleroderma, SLE and RA, including outcome measurements, clinical trials and disease manifestations. She has published over 450 peer-reviewed articles, 15 chapters, 500 abstracts and several Cochrane meta-analysis reviews. Mentoring of research students and trainees numbers more than 125. She has received the Distinguished Investigator Award from the Canadian Rheumatology Association, Rheumatologist of the Year from the Ontario Rheumatology Association, Department of Medicine Research Achievement Award, and the Dean’s Award of Excellence in Research. She has been inducted into the Canadian Academy of Health Sciences.

     

×